^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PeptiCRAd-1

    i
    Other names: PeptiCRAd-1, VALO-D102
    Associations

    News

    Trials
    Company:
    Valo Tx
    Drug class:
    CD40 stimulant, CD40L stimulant, OX40 ligand stimulant
    Related drugs:
    Associations

    News

    Trials
    12ms
    START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Valo Therapeutics Oy | Trial completion date: Jan 2024 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1
    almost2years
    START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Valo Therapeutics Oy | Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Feb 2023
    Enrollment open • Trial initiation date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • MAGEA3 (MAGE Family Member A3)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1
    over2years
    START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Valo Therapeutics Oy
    New P1 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • MAGEA3 (MAGE Family Member A3)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1